Scientifica / 2012 / Article / Tab 3

Review Article

Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?

Table 3

ACCF/AHA and ESC Guidelines for treating asymptomatic LVSD (recommendation; Level of Evidence).

Guidelines 2009 [139]
Guidelines 2005 [48]

ACE inhibitor(I; A)(I; A)
Angiotensin receptor blockersPost-MI and intolerant of ACE I (I; B) 
No prior MI and intolerant of ACE I (IIa; C)
Post-MI (I; A)
Beta blockersRecent or remote MI (I; A) 
No prior MI (I; C)
Post-MI (I; B)
Implantable cardioverter defibrillator≥40 days post-MI and LVEF ≤30% on optimal medical therapy (IIa; B) 
Nonischemic cardiomyopathy and LVEF ≤30% on optimal medical therapy (IIb; C)

ACCF/AHA: American College of Cardiology Foundation/American Heart Association; ESC: European Society of Cardiology; LVSD: left ventricular systolic dysfunction; ACE inhibitor: angiotensin converting enzyme inhibitor; MI: myocardial infarction; LVEF: left ventricular ejection fraction.
Reprinted, with permission, from Atherton, 2012 [140].